The Use of 5-Alpha Reductase Inhibitors to Manage Benign Prostatic Hyperplasia and the Risk of All-cause Mortality

OBJECTIVE: To compare the risk of mortality among men treated for benign prostatic hyperplasia (BPH) with 5 alpha-reductase inhibitors (5ARI) to those treated with alpha-blockers (AB) in community practice settings. METHODS: We employed a retrospective matched cohort study in 4 regions of an integra...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Urology
Egile Nagusiak: Wallner, Lauren P., DiBello, Julia R., Li, Bonnie H., Van Den Eeden, Stephen K., Weinmann, Sheila, Ritzwoller, Debra P., Abell, Jill E., D’Agostino, Ralph, Loo, Ronald K., Aaronson, David S., Horwitz, Ralph I., Jacobsen, Steven J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8080272/
https://ncbi.nlm.nih.gov/pubmed/29906480
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.urology.2018.05.033
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak